Pieris Pharmaceuticals has been granted a patent for a fusion polypeptide that targets both CD137 and GPC3, potentially aiding in the treatment of various tumors. The polypeptide can be used as an anti-cancer agent or immune modulator. The patent also covers methods of production and therapeutic applications. GlobalData’s report on Pieris Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Pieris Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Pieris Pharmaceuticals, Active contour based diagnosis models was a key innovation area identified from patents. Pieris Pharmaceuticals's grant share as of February 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Fusion polypeptide binding cd137 and gpc3 for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Pieris Pharmaceuticals Inc

A recently granted patent (Publication Number: US11919931B2) discloses a fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3). The fusion polypeptide consists of at least two subunits, with the first subunit specific for CD137 and the second subunit specific for GPC3. The GPC3-specific lipocalin mutein within the fusion polypeptide contains mutated amino acid residues compared to the linear polypeptide sequence of mature human lipocalin 2 (hNGAL). Additionally, the patent details various sets of amino acid substitutions within the GPC3-specific lipocalin mutein, removing the natural N-glycosylation site at position 65.

Furthermore, the patent outlines that the GPC3-specific lipocalin mutein in the fusion polypeptide does not have an N-glycosylation site and can comprise specific amino acid sequences selected from a group of sequences provided in the patent. The fusion polypeptide can also include specific amino acid sequences shown in various SEQ ID NOs listed in the patent. These claims highlight the innovative fusion polypeptide's design and specificity for binding CD137 and GPC3, offering potential applications in targeted therapies and diagnostic tools within the medical field.

To know more about GlobalData’s detailed insights on Pieris Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies